Skip to content

News Center | Georgia Institute of Technology Georgia Institute of Technology

Search

Search form

  • Facebook
  • Twitter
  • YouTube
  • LinkedIn
  • News Home
  • Campus Map
  • Directory
  • Offices

News Center

Menu
Close
  • Calendar
  • Categories
    • Business and Economic Development
    • Campus and Community
    • Earth and Environment
    • Health and Medicine
    • Science and Technology
    • Society and Culture
    • Feature Stories
  • Media Contacts
  • Experts
    • Find an Expert
    • Featured Expert
  • Daily Digest
  • The Whistle
    • Home
    • Classifieds
    • Archives
  • Social Media
  • Subscribe
  • You are here:
  • GT Home
  • Georgia Tech NewsCenter
  • Home
  • Data Detectives Shift Suspicions in Alzheimer's from Usual Suspect to Inside Villain

Health and Medicine Science and Technology

Data Detectives Shift Suspicions in Alzheimer's from Usual Suspect to Inside Villain

By Ben Brumfield | February 19, 2018 • Atlanta, GA

Amyloid beta and p-tau illustration NIA NIH
Click image to enlarge

Artist's rendering of amyloid-beta plaque (beige clumps) outside of neurons and neurofibrillary tangles (blue) inside of neurons. Credit: National Institute on Aging, National Institutes of Health 

Download Image
MORE PHOTOS

The mass pursuit of a conspicuous suspect in Alzheimer’s disease may have held back research success for decades. Now, a new data analysis that has untangled evidence amassed in years of Alzheimer’s studies encourages researchers to refocus their investigations.

Heaps of plaque formed from amyloid-beta that accumulate in afflicted brains are what stick out under the microscope in tissue samples from Alzheimer’s sufferers, and that eye-catching junk has long seemed an obvious culprit in the disease. But data analysis of the cumulative evidence doesn’t support giving so much attention to that usual suspect, according to a new study from the Georgia Institute of Technology.

Though the bad amyloid-beta protein does appear to be an accomplice in the disease, the study has pointed to a seemingly more likely red-handed offender, another protein-gone-bad called phosphorylated tau (p-tau). What’s more, the Georgia Tech data analysis of multiple studies done on mice also turned up signs that multiple biochemical actors work together in Alzheimer’s to tear down neurons, the cells that the brain uses to do its work.

Suspect line-up: P-tau implicated, plaque not so much

And the corrupted amyloid-beta that appeared more directly in cahoots with p-tau in the sabotage of brain function was not tied up in that plaque. In the line-up of the biochemical suspects examined, principal investigator Cassie Mitchell, an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, said the data pointed to a pecking order of culpability.

“The most important one would be the level of phosphorylated tau present. It had the strongest connection with cognitive decline,” Mitchell said. “The correlation with amyloid plaque was there but very weak; not nearly as strong as the correlation between p-tau and cognitive decline.”

Mitchell, a biomedical informaticist, and first author Colin Huber statistically analyzed data gleaned from 51 existing lab studies in mice genetically augmented with a human form of Alzheimer’s. They published their analysis in the current edition of the Journal of Alzheimer’s Disease. The research was funded by the National Institutes of Health.

The crime: Eviscerating the brain

One look at an image of an Alzheimer’s afflicted brain is unflinching testimony to the disease’s cruelty: It destroys of up to 30 percent of a brain’s mass, carving out ravines and depositing piles of molecular junk, most visibly amyloid plaque.

The plaque builds up outside of neurons, while inside neurons, p-tau forms similar junk known as neurofibrillary tangles that many researchers believe push the cells to their demise. But many biochemical machinations behind Alzheimer’s are still unknown, and the fight to uncover them has vexed researchers for decades.

Since the first patient was diagnosed by Dr. Aloysius Alzheimer between 1901 and 1906, little medical progress has been made. Though some available medications may mitigate symptoms somewhat, none significantly slow disease progression, let alone stop it.

Alzheimer’s mostly strikes late in life. Longer lifespans in industrialized countries have ballooned the caseload, advancing the disease to a major cause of death.

Meet the syndicate: Assassin, accomplices, stooges

Even though p-tau showed the strongest correlation with cognitive decline, and amyloid-beta only a slight correlation, that doesn’t mean that p-tau is committing the crime inside cells all by itself while amyloid loiters in spaces outside of cells in large gangs, creating a distraction. Mitchell’s data analysis has pointed to dynamics more enmeshed than that.

“Though the study had clear trends, it also had a good bit of variance that would indicate multiple factors influencing outcomes,” Mitchell said. And a particular manifestation of amyloid-beta has piqued the researchers’ ire.

Little pieces are water soluble, that is, not tied up in clumps of plaque. The data has shown that these tiny amyloids may be up to no good. After p-tau levels, the study revealed that those of soluble amyloid-beta had the second-strongest correlation with cognitive decline.

“Lumpy amyloid-beta, the stuff we see, ironically doesn’t correlate as well with cognitive decline as the soluble amyloid,” Mitchell said. “The amyloid you don’t see is like the sugar in your tea that dissolves and hits your taste buds versus the insoluble amyloid, which is more like the sugar that doesn’t dissolve and stays at the bottom of the cup.”

Some Alzheimer’s researchers have cited evidence indicating that free-floating amyloid helps produce the corrupted p-tau via a chain of reactions that centers around GSK3 (Glycogen synthase kinase 3), an enzyme that arms tau with phosphorous, turning it into a potential biochemical assassin.

Incidentally, Mitchell’s study also looked at un-phosphorylated tau and found its levels do not correlate with cognitive decline. “That makes sense,” Mitchell said. “Regular tau is the backbone of our neurons, so it has to be there.”

Also, p-tau is a normal part of healthy cells, but in Alzheimer’s it is wildly overproduced.

Massive dataset: 528 mice rat out p-tau

One advantage of data mining 51 existing studies versus doing one new lab experiment, is that the cumulative analysis adds the sample sizes of so many studies together for a whopping grand total. Mitchell’s analysis encompassed results from past experiments carried out on, all totaled, 528 Alzheimer’s mice.

A previous study Mitchell led had already indicated that amyloid-beta plaque levels may not be the most productive target for drug development. Separate reports by other researchers on failed human trials of drugs that fought plaque would seem to corroborate this.

Mitchell’s prior analysis examined lab studies that used an Alzheimer’s lab mouse model that did not allow for the study of p-tau. Mitchell’s current analysis covered studies involving a different mouse model that did allow for the observation of p-tau.

Mitchell’s latest findings have corroborated the prior study’s findings on amyloid, and also added p-tau as a key suspect in cognitive decline.

Principal investigator: My take on possible treatments

To arrive at the 51 studies with data suitable for inclusion in their analysis, Mitchell’s research team sifted through hundreds of Alzheimer’s research papers, and over time, Mitchell has examined a few thousand herself. She has gained some impressions of how biomedical research may need to tackle the disease’s slippery biochemical labyrinth.

“When we see multifactorial diseases, we tend to think we’ll need multifactorial treatments,” Mitchell said. “That seems to be working well with cancer, where they combine chemotherapy with things like immunotherapy.”

Also, Alzheimer’s diagnosticians might be wise to their adopt cancer colleagues’ early detection stance, she said, as Alzheimer’s disease appears to start long before amyloid-beta plaque appears and cognitive decline sets in.

Above all, basic research should cast a broader net.

“I think p-tau is going to have to be a big part,” she said. “And it may be time to not latch onto amyloid-beta plaque so much like the field has for a few decades.”

Did you know? Cassie Mitchell is also an Olympic medalist! Watch her video here.

Also READ: Our feature on Alzheimer’s research – Killing the Mind First

Like this article? Get our email newsletter here.

Georgia Tech’s Connor Yee, Taylor May, and Apoorva Dhanala coauthored the study. Funding was provided by the National Institute of Neurological Disorders and Stroke at the National Institutes of Health (grants NS069616, NS098228, and NS081426). Any findings or conclusions are those of the authors and not necessarily of the sponsor.

Additional Photos

  • Alzheimer's brain shrinkage illustration NIA NIH
     

    Alzheimer's brain shrinkage illustration NIA NIH

    The brain of an Alzheimer's sufferer can dramatically lose mass and shrink. In particular, center structures of the brain usually diminish early on. One such region susceptible to early and severe damage is the hippocampus, which can lead to memory loss and disorientation. Illustration credit: National Institute on Aging, National Institutes of Health

    Download Image
  • Informaticist Cassie Mitchell studies Alzheimer's
     

    Informaticist Cassie Mitchell studies Alzheimer's

    Informaticist and biomedical engineer Cassie Mitchell studies Alzheimer's Disease by statistically analyzing data produced by dozens of peer-reviewed published Alzheimer's studies. She looks for correlations between the presence of biochemical factors and cognitive decline. Credit: Georgia Tech / Rob Felt

    Download Image
  • Alzheimer's brain NIH
     

    Alzheimer's brain NIH

    The brain of an Alzheimer's sufferer in a severe stage can show extreme destruction of brain mass. Credit: National Institutes of Health

    Download Image
  • Amyloid-beta plaque under microscope
     

    Amyloid-beta plaque under microscope

    Along with blood vessels (red) and nerve cells (green), this mouse brain shows abnormal protein clumps known as plaques (blue). Georgia Tech / Levy Wood

    Download Image
  • Alzheimer's diagram of biochemical processes
     

    Alzheimer's diagram of biochemical processes

    Image not for redistribution without express permission of copyright holder. A diagram shows what some researchers believe is the pathway to the accumulation of free amyloid beta, amyloid beta plaque, and subsequently phosphorylated tau, which forms neurofibrillary tangles. Illustration credit: Cell Signaling Technology / used with permission to Georgia Tech

    Download Image

Contact Information

Writer & Media Representative: Ben Brumfield (404-660-1408)

Georgia Institute of Technology
177 North Avenue
Atlanta, Georgia  30332-0181  USA

Categories

Health and Medicine Science and Technology

News Categories

  • Business and Economic Development
  • Campus and Community
  • Earth and Environment
  • Health and Medicine
  • Science and Technology
  • Society and Culture

Expert Voices

James Dahlman

James Dahlman is an assistant professor in the Wallace H. Coulter Department of Biomedical Engineering.

Gene therapy eyes medical breakthrough
James Dahlman
Wallace H. Coulter Department of Biomedical Engineering

Featured Videos

Seth Osekre, a custodian in Facilities Management, follows safety protocols when cleaning. (Video by Allison Carter)

2020 graduate TJ Weiler talks about his journey to earning a Georgia Tech degree.

Georgia Tech Resources

  • Offices & Departments
  • News Center
  • Campus Calendar
  • Special Events
  • GreenBuzz
  • Institute Communications
  • Visitor Resources
  • Campus Visits
  • Directions to Campus
  • Visitor Parking Information
  • GTvisitor Wireless Network Information
  • Georgia Tech Global Learning Center
  • Georgia Tech Hotel & Conference Center
  • Barnes & Noble at Georgia Tech
  • Ferst Center for the Arts
  • Robert C. Williams Paper Museum

Colleges, Instructional Sites & Research

  • Colleges
  • College of Computing
  • College of Design
  • College of Engineering
  • College of Sciences
  • Ivan Allen College of Liberal Arts
  • Scheller College of Business
  • Instructional Sites
  • Georgia Tech-Lorraine
  • Georgia Tech-Savannah
  • Georgia Tech-Shenzhen
  • Georgia Tech Online
  • Professional Education
  • The Language Institute
  • Global Footprint
  • Global Engagement
  • Research
  • Georgia Tech Research Institute
  • Research at Georgia Tech
  • Executive Vice President for Research

Student & Parent Resources

  • Student Resources
  • Apply
  • BuzzPort
  • Buzzcard
  • Career Center
  • Co-ops & Internships
  • Commencement
  • Library
  • Student Life
  • Student Entrepreneurship
  • Study Abroad
  • T-Square
  • Parent Resources
  • Parent and Family Programs
  • Dean of Students
  • Scholarships & Financial Aid

Employee, Alumni, & Other Resources

  • Employees
  • Administration and Finance
  • Advising & Teaching
  • Faculty Affairs
  • Faculty Hiring
  • Human Resources
  • Office of the Provost
  • TechWorks
  • Alumni
  • Alumni Association
  • Alumni Career Services
  • Giving Back to Tech
  • Outreach
  • Startup Companies
  • Economic Development
  • Industry Engagement
  • Government & Community Partners
  • Professional Education
Map of News Center | Georgia Institute of Technology

Georgia Institute of Technology
North Avenue, Atlanta, GA 30332
Phone: (404) 894-2000

  • Contact Us
  • Site Feedback
  • Tech Lingo
  • Emergency Information
  • Legal & Privacy Information
  • Human Trafficking Notice
  • Accessibility
  • Accountability
  • Accreditation
  • Employment
Georgia Tech

© Georgia Institute of Technology